Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune & Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for JAK1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | JAK1 Full-Length & Kinase Domain Recombinant Protein; High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW. | View JAK1 Products |
| Gene Delivery | JAK1 Promise-ORF / Lentivirus; Full-length ORF for stable cell lines and pathway reporter assays. | View JAK1 Products |
| Assay Control Ab | Anti-JAK1 & Anti-Phospho-JAK1 (Y1034/1035) Antibody Pair; Recombinant rabbit mAb for Western, ELISA, and ICC. | View JAK1 Products |
| Validator | JAK1 siRNA Set; For knockdown and specificity verification. | View JAK1 Products |
| Related Target A | JAK2; Critical off-target liability; hematologic toxicity counter-screening. | View JAK2 Products |
| Related Target B | TYK2; Emerging autoimmune target; combination and selectivity panel. | View TYK2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity & Off-target Liability (JAK2/JAK3/TYK2) | Human JAK1/JAK2/JAK3/TYK2 Kinase Domain Proteins, >95% purity, Sequence Verified, for orthogonal IC50 profiling |
| Drug Resistance & Activating Mutations | JAK1 WT & Custom Mutant Recombinant Kinase Proteins; Theoretical MW Confirmed |
| Lack of Assay Controls | Anti-JAK1 & Anti-Phospho-JAK1 Antibodies included for Western/ELISA |
| False Positives / Specificity Checks | JAK1 siRNA Set included for target knockdown verification |
Global Clinical Landscape & Future Outlook
The race for JAK1 therapeutics is intensifying, with major players shifting focus from first-generation pan-JAK inhibitors to highly selective JAK1 small molecules and next-generation PROTAC degraders. As approved therapies expand across rheumatology, dermatology, and gastroenterology, the next wave of R&D is targeting refractory patient populations and improved cardiovascular safety profiles through allosteric inhibition and tissue-specific delivery. Key players include AbbVie (Upadacitinib), Eli Lilly (Baricitinib), Pfizer (Tofacitinib, Abrocitinib), Gilead/Galapagos (Filgotinib), and Japan Tobacco (Peficitinib). Emerging modalities include PROTAC degraders (e.g., Kymera Therapeutics), topical inhibitors (e.g., Incyte), and allosteric modulators (e.g., BMS targeting TYK2/JAKs).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective JAK1 Inhibitor | AbbVie, Eli Lilly, Pfizer, Gilead Sciences | Rheumatoid Arthritis, Atopic Dermatitis, Ulcerative Colitis | Kinase Selectivity Panel (Need purified JAK1/JAK2/JAK3/TYK2 proteins) |
| JAK1 PROTAC / Degrader | Kymera Therapeutics, Preclinical / Academic Consortiums | Refractory Autoimmune, Oncology | Cellular Ternary Complex Assay (Need JAK1 Lentivirus + WT/Mutant proteins) |
| Pan-JAK / JAK1-3 Inhibitor | Japan Tobacco, others | Psoriasis, Alopecia Areata, Myeloproliferative Neoplasms | Broad JAK Family Counter-Screen (Need full-length & kinase domain proteins) |
| Topical Inhibitors | Incyte | Alopecia Areata, Vitiligo | Skin Penetration & Local Potency (Need high-purity WT proteins) |
| Allosteric Modulators | BMS (TYK2/JAKs) | Psoriasis, IBD | Domain-Specific Assays (Need Pseudokinase Domain Reagents) |
Molecular Differentiation & Assay Strategy
For best-in-class JAK1 drug development, molecular differentiation must address selectivity, binding mode, delivery, and safety. Key factors include:
- Selectivity: JAK1 vs JAK2 (avoid hematologic toxicity), JAK1 vs JAK3 (reduce immunosuppression), and JAK1 vs TYK2 (preserve type I interferon/IL-12/23 pathways). Ideal JAK1 inhibitors should show at least 10-50 fold selectivity over JAK2.
- Binding Mode & Resistance Barrier: Type I ATP-competitive inhibitors are prone to resistance from activation loop mutations; Type II (DFG-out) or allosteric inhibitors can bypass gatekeeper mutations. Assays must evaluate WT vs common mutant binding affinities and thermal stability.
- Delivery & Exposure: Oral systemic exposure is standard, but gut-restricted prodrugs are emerging for IBD. For PROTACs, key metrics include ternary complex formation efficiency and E3 ligase selectivity.
- Safety & Off-target Control: Beyond JAK family, off-target liabilities (e.g., kinases, GPCRs) must be screened using broad panels.
Live JAK1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: